Multiple myeloma (MM) is a heterogeneous malignancy of plasma cells. Despite
improvement in the prognosis of MM patients after the introduction of many new drugs in the …

The emergence of new drugs is a major feature of the treatment history of multiple myeloma
(MM), which also reflects the current incurability of MM. As a unique member of cyclin …

* Correspondence to: Ki-Young Lee; Email: kylee@ ucalgary. ca Submitted: 07/30/12;
Accepted: 08/20/12 http://dx. doi. org/10.4161/cc. 21886 investigate the link between the …

Lenalidomide, an immunomodulatory drug (IMiD), is highly active and broadly used for the
treatment of multiple myeloma. Despite high initial remission rates, patients frequently …

The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective
treatments for multiple myeloma. However, virtually all patients eventually relapse due to …

8503 Background: Deregulation of Cdk4 or Cdk6 is a hallmark in cancer. However,
conventional cancer therapy centers on empirical cytotoxic killing. Targeting the cell cycle …

Purpose: Deletions of chromosome 1 have been described in 7% to 40% of cases of
myeloma with inconsistent clinical consequences. CDKN2C at 1p32. 3 has been identified …

Through the recent elucidation of molecular and cellular processes in multiple myeloma
(MM) pathogenesis that effect well-defined proliferative and survival pathways, a number of …

Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target
effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact …

Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …